Stock comparison
Merck & Co., Inc. is 141.3x more valuable than Xeris Biopharma Holdings, Inc. by market capitalization ($360.96 B vs $2.56 B). Compare market value, revenue, profit, margins, filings, and source pages in one place.
Quick answer
MRK is larger
Merck & Co., Inc. is 141.3x more valuable than Xeris Biopharma Holdings, Inc. by market capitalization ($360.96 B vs $2.56 B).
Market value leader
MRK
Merck & Co., Inc. is 141.3x more valuable than Xeris Biopharma Holdings, Inc. by market capitalization ($360.96 B vs $2.56 B).
Revenue leader
MRK
XERS: $291.85M vs MRK: $65.01B.
Profit leader
MRK
XERS: $554.00K vs MRK: $18.25B.
Margin leader
MRK
XERS: 0.2% vs MRK: 28.1% net margin.
| Metric | XERS | MRK |
|---|---|---|
| Market cap | $2.56 B | $360.96 B |
| US-listed rank | #1919 | #30 |
| Revenue (latest FY) | $291.85M | $65.01B |
| Net income (latest FY) | $554.00K | $18.25B |
| Net margin | 0.2% | 28.1% |
| P/E (trailing FY) | 4612.1x | 19.8x |
| SEC filings | 290 | 1,000 |
Jump from this comparison into the underlying pages for market value, annual fundamentals, and company filing history.
Market cap uses refreshed market data. Revenue, net income, margins, and trailing fiscal-year P/E use annual company facts from filings. If a metric is missing, the source data did not have a clean recent annual value for that company.
Merck & Co., Inc. is 141.3x more valuable than Xeris Biopharma Holdings, Inc. by market capitalization ($360.96 B vs $2.56 B).
In their latest fiscal years, Xeris Biopharma Holdings, Inc. reported $291.85M in revenue while Merck & Co., Inc. reported $65.01B.
Full pages: Xeris Biopharma Holdings, Inc. and Merck & Co., Inc., or browse the full rankings.